Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.
Case Inclusion Criteria:
- Newly diagnosed (within 90 days) with cancer or a recurrence of a cancer diagnosed > 5 years ago of one of the following subtypes: Invasive Brain, Breast, Bladder, Cervical, Colorectal, Endometrial, Esophageal, Gastric, Head and Neck, Hepatobiliary, Lung, Ovarian, Pancreatic, Prostate, Renal, Sarcoma, Thyroid; Leukemia, Lymphoma, Multiple Myeloma.
- Able and willing to provide informed consent.
- ≥ 40 years of age.
Case Exclusion Criteria:
- Currently receiving any treatment for cancer.
- Currently taking any demethylating agents/DNA hypomethylating agents.
- Simultaneously diagnosed with two or more invasive cancers.
- Diagnosed with any invasive or non-invasive cancer in addition to the index cancer in the last 5 years.
- Currently diagnosed with any chronic hematopoietic cancer (e.g., chronic CLL) in addition to the index cancer.
- Currently diagnosed with any myelodysplastic syndromes and/or precursor hematologic conditions (e.g., MGUS) in addition to the index cancer.
- Women who are known to be pregnant (self-reported).
Control Inclusion Criteria:
- Not diagnosed with any cancer in the last 5 years (non-invasive cancer is allowed).
- Able and willing to provide informed consent.
- ≥ 40 years of age.
Control Exclusion Criteria:
- Currently receiving any treatment for cancer.
- Currently taking any demethylating agents/DNA hypomethylating agents.
- Women who are known to be pregnant (self-reported).
Eligibility last updated 9/26/22. Questions regarding updates should be directed to the study team contact.